TUSTIN, Calif., May 30 AMDL, Inc. (Amex: ADL),www.amdl.com ,a world leader in specialty pharmaceuticals with operations inShenzhen, Jiangxi and Jilin, China, announced today the launch of new productsfor its GOODNAK anti-aging line.
The company is releasing the new GOODNAK formulations in partnership withJJB, the subsidiary of AMDL's Chinese subsidiary Jade Pharmaceutical Inc.(JPI). Scheduled to be released next month, the GOODNAK product includesHuman Placental Histosolution, and effective and key component in anti-agingproducts which has been shown to give skin a youthful look by increasing cellrenewal and smoothening fine lines.
JJB has applied to Chinese regulatory authorities for product approval andanticipates sanction this month. Based on the general market information, theproposed pricing for the new GOODNAK products is anticipated to beapproximately (U.S.)$40.00 per unit with a 60% gross profit margin.
Frank Zhang, managing Director of JPI, stated that, "the new GOODNAKconsumer products are expected to be highly popular and anticipated salesgrowth is expected to significantly increase in 2008 and beyond. This productmay also be extremely an exceptionally good candidate for export to the NorthAmerican and European beauty care markets."
AMDL, Inc. is a global specialty pharmaceutical company. The Company isheadquartered in Tustin, California with operations in Shenzhen, Jiangxi, andJilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDLis devoted to the research, development, manufacture, and marketing ofdiagnostic, pharmaceutical, nutritional supplement, and cosmetic productscurrently in China. The company employs approximately 320 people in the U.S.and China. More information about AMDL and its products can be obtained athttp://www.amdl.com.
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer marketin the world: China. AMDL, through its subsidiaries, Jade currentlymanufactures large volume injection fluids, tablets and other relatedproducts, holding licenses for 133 products. It also manufactures 107 generic,over the counter and supplemental pharmaceutical products under certifiedChinese Good Manufacturing Practice (CGMP) standards.
IR Contact: Mr. Paul KnopickDirect: 949.707.5365 Voicemail: 714.505.4460
SOURCE AMDL, Inc.